{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:11:42Z","timestamp":1767172302457,"version":"build-2238731810"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the most common non-cutaneous malignancy in men and leads to the second most common cause of cancer related mortality in men. Early detection of PCa allows for a potentially curative intervention. Most men will live over a decade from the time of their PCa diagnosis. Thus, treatments must balance curative interventions with their impact on quality of life. Radical prostatectomy (RP) is one such potentially curative intervention but often leads to erectile dysfunction (ED) and urinary incontinence (UI). Approximately 90,000 RPs are performed each year in the USA. Post-operative ED and UI is thought to occur in part from traumatic peripheral nerve injury (TPNI) to the neurovascular bundles that surround the prostate. Thus, patients undergoing RP may be a population that would benefit from clinical studies that look at TPNI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a single-institution, double-blinded placebo-controlled, randomized clinical trial in which patients immediately post-RP receive either 4-aminopyrdine (4AP) or placebo in a 1:1 fashion. The primary outcome is evaluation of the efficacy of 4AP in accelerating the early return of baseline erectile and urinary function post-radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study is critical as it could reduce the morbidity associated with RP, a commonly performed operation, and identify a patient population that may greatly benefit into further TPNI research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03701581. Prospectively registered on October 10, 2018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-08102-z","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:01:31Z","timestamp":1716264091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmed","family":"Ghazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Osinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-7118","authenticated-orcid":false,"given":"John","family":"Elfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"8102_CR1","first-page":"35","volume":"6","author":"Z Hamilton","year":"2014","unstructured":"Hamilton Z, Mirza M. Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective. Research and Reports in Urology. 2014;6:35\u201341.","journal-title":"Research and Reports in Urology"},{"issue":"6","key":"8102_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.juro.2017.12.060","volume":"199","author":"JK Jo","year":"2018","unstructured":"Jo JK, et al. Effect of starting penile rehabilitation with sildenafil immediately after robot-assisted laparoscopic radical prostatectomy on erectile function recovery: a prospective randomized trial. J Urol. 2018;199(6):1600\u20136.","journal-title":"J Urol"},{"issue":"7","key":"8102_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/j.1743-6109.2009.01269.x","volume":"6","author":"P Teloken","year":"2009","unstructured":"Teloken P, et al. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009;6(7):2032\u20138.","journal-title":"J Sex Med"},{"issue":"4","key":"8102_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.eururo.2008.06.083","volume":"54","author":"F Montorsi","year":"2008","unstructured":"Montorsi F, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54(4):924\u201331.","journal-title":"Eur Urol"},{"issue":"2","key":"8102_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2016.01.026","volume":"70","author":"J Walz","year":"2016","unstructured":"Walz J, Epstein JI, Ganzer R, Graefen M, Guazzoni G, Kaouk J, Menon M, Mottrie A, Myers RP, Patel V, Tewari A, Villers A, Artibani W. A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. Eur Urol. 2016;70(2):301\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.026. Epub 2016 Feb 2 PMID: 26850969.","journal-title":"Eur Urol"},{"key":"8102_CR6","unstructured":"AMPYRA (dalfampridine) Extended release tablets prescribing information and medication guide. Acorda Therapeutics, Inc. January 2013."},{"key":"8102_CR7","doi-asserted-by":"publisher","unstructured":"Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR. MSF203, MS-F204, and extension study investigators. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two phase 3 clinical trials. Mult Scler. 2015;21(10):1322\u201331.\u00a0https:\/\/doi.org\/10.1177\/1352458514563591.","DOI":"10.1177\/1352458514563591"},{"key":"8102_CR8","unstructured":"Open-label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in patients with multiple sclerosis who participated in MS-F204 Trial, NCT00649792, Info provided by: Acorda Therapeutics; Open-label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in patients with multiple sclerosis who participated in MS-F203 Trial, NCT00648908, Info provided by: Acorda Therapeutics; Open-label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in patients with multiple sclerosis, NCT00654927, Info provided by: Acorda Therapeutics"},{"key":"8102_CR9","unstructured":"Safety and efficacy of oral fampridine-SR for the treatment of spasticity resulting from spinal cord injury, NCT00041717, Info provided by: Acorda Therapeutics; Safety and efficacy of oral fampridine-sustained release (SR) for the treatment of spasticity resulting from spinal cord injury, NCT01683838, Info provided by: Acorda Therapeutics."},{"key":"8102_CR10","first-page":"CD001330","volume":"4","author":"A Solari","year":"2002","unstructured":"Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Solari, Alessandra, ed. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev. 2002;4:CD001330.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"8102_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.sc.3101947","volume":"45","author":"DD Cardenas","year":"2007","unstructured":"Cardenas DD, Ditunno J, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007;45(2):158\u201368.","journal-title":"Spinal Cord"},{"key":"8102_CR12","unstructured":"A safety and efficacy of oral prolonged-release fampridine (BIIB041) in Japanese participants with multiple sclerosis (MOTION-JAPAN), NCT01917019, Info provided by: Biogen"},{"key":"8102_CR13","unstructured":"Prolonged-release fampridine as adjunct therapy to active motor training in MS patients, NCT02146534, Info provided by: Clinique Neuro-Outaouais"},{"issue":"429","key":"8102_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/01621459.1995.10476494","volume":"90","author":"JM Robins","year":"1995","unstructured":"Robins JM, Rotnitzky A. Semiparametric efficiency in multivariate regression models with missing data. J Am Stat Assoc. 1995;90(429):122\u20139.","journal-title":"J Am Stat Assoc"},{"key":"8102_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563","volume-title":"Statistical analysis with missing data","author":"RJA Little","year":"2002","unstructured":"Little RJA, Rubin DB. Statistical analysis with missing data. NJ, John Wiley and Sons: Hoboken; 2002."}],"updated-by":[{"DOI":"10.1186\/s13063-024-08518-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08102-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T03:03:24Z","timestamp":1727838204000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08102-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8102"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08102-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-024-08518-7","URL":"https:\/\/doi.org\/10.1186\/s13063-024-08518-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Subjects Review Board (RSRB) at the University of Rochester Medical Center granted approval on 12\/11\/2019. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Attached.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"Author contributions were reviewed by the respective Conflict of Interest Committee at both institutions (URMC, PSU). The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"332"}}